Results 201 to 210 of about 442,503 (290)

The global extent of polypharmacy in neonatal intensive care: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Pharmaceutical treatment in the neonatal intensive care unit (NICU) is challenging, with neonates often receiving multiple drugs during hospitalization. Given their physiological immaturity, polypharmacy raises concerns about potential adverse effects, drug–drug interactions and the risk of supratherapeutic or subtherapeutic treatment.
Mia Finserås Bretun   +6 more
wiley   +1 more source

The placental transfer of nirmatrelvir using the ex vivo human placental perfusion model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Nirmatrelvir is an effective therapeutic option for COVID‐19 infection and is often administered after symptom onset in pregnant individuals, but few data are available on the associated fetal exposure. The placental perfusion model evaluates maternal–fetal drug transfer across the human placenta and thus can determine fetal drug exposure.
Magdalene Zabek   +5 more
wiley   +1 more source

Population pharmacokinetics of levetiracetam in term neonates with hypoxic–ischemic encephalopathy and therapeutic hypothermia: The LEVNEONAT‐1 study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim This study aimed to describe the pharmacokinetics (PK) of levetiracetam (LEV) in term neonates treated for neonatal seizures secondary to hypoxic–ischemic encephalopathy (HIE). Methods Fifteen neonates were included and received a loading dose ranging from 30 to 60 mg/kg followed by eight maintenance doses corresponding to one‐fourth of the loading
Léo Mimram   +9 more
wiley   +1 more source

Are pregnancy‐ and lactation‐related eligibility criteria in cardiovascular clinical trials underpinned by drug safety data?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To quantify the prevalence of pregnancy‐, lactation‐ and reproductive potential‐related eligibility criteria in cardiovascular clinical trials and to evaluate whether they are supported by drug‐specific safety data. Methods We analysed randomized phase 3 and phase 4 cardiovascular clinical trials registered on ClinicalTrials.gov between 1 January ...
Jera Gurakuqi   +6 more
wiley   +1 more source

Mitochondria‐endoplasmic reticulum organelle glue as maturation promoter for origination/dimensional dual‐cross cardiomyocytes

open access: yesBMEMat, EarlyView.
Mitochondria‐endoplasmic reticulum contact sites (MERCS) are areas where the mitochondria and endoplasmic reticulum closely interact. In this study, we utilize synthetic organelle glues to artificially engineer MERCS for regulating cardiomyocyte development, through which the immature and chemo‐plasticity issues of undifferentiated cells are addressed.
Wei Tang   +9 more
wiley   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

open access: yesBMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang   +8 more
wiley   +1 more source

Authentic and Sustained Family Partnership in Neonatal and Pediatric Research. [PDF]

open access: yesPediatrics
Franck LS   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy